文献速递心脑血管急症消化、代谢与肾脏急症

21国前瞻性队列研究:精制谷物摄入与心血管疾病及死亡风险的关联

Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study.
PubMed 文献 · BMJ · 2021-02-03
一句话结论精制谷物摄入最高组(≥350 g/天或约7份/天)与全因死亡、主要心血管事件及复合终点风险升高相关,全谷物或白米无显著关联。

该研究基于PURE前瞻性队列,纳入21个国家148 858名参与者,中位随访9.5年,排除基线心血管病后分析137 130人。采用国家特异性经验证的食物频率问卷评估精制谷物、全谷物和白米摄入,主要终点为死亡或主要心血管事件(心血管死亡、非致死性心梗、卒中或心衰)的复合终点。随访期间9.2%(n=12 668)发生复合终点事件。与精制谷物摄入最低组(<50 g/天)相比,最高组(≥350 g/天或约7份/天)全因死亡HR 1.27(95%CI 1.11–1.46;趋势P=0.004),主要心血管事件HR 1.33(95%CI 1.16–1.52;趋势P<0.001),复合终点HR 1.28(95%CI 1.15–1.42;趋势P<0.001);精制谷物摄入越高收缩压越高。全谷物或白米摄入与健康结局无显著关联。

要点

  • 精制谷物最高摄入组(≥350 g/天或约7份/天)与全因死亡风险升高相关(HR 1.27,95%CI 1.11–1.46)。
  • 精制谷物最高摄入组与主要心血管事件风险升高相关(HR 1.33,95%CI 1.16–1.52)。
  • 精制谷物最高摄入组与死亡或主要心血管事件复合终点风险升高相关(HR 1.28,95%CI 1.15–1.42)。
  • 精制谷物摄入越高收缩压越高。
  • 全谷物或白米摄入与健康结局无显著关联。

适用人群与场景

  • PURE研究21个国家148 858名参与者,中位随访9.5年;分析排除基线心血管病后为137 130人。
  • 原文未提及急诊、ICU或院前场景的专门适用人群或排除标准。

诊断标准与关键阈值

  • 原文未提及诊断标准或关键阈值;仅按精制谷物摄入量分组,最高组为≥350 g/天或约7份/天,最低组为<50 g/天。

处置流程与药物剂量

  • 原文未提及急诊或ICU处置流程及药物剂量。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性队列研究(PURE),21个国家,148 858名参与者,中位随访9.5年;排除基线心血管病后分析137 130人。
  • 主要终点:死亡或主要心血管事件(心血管死亡、非致死性心梗、卒中或心衰)的复合终点;随访期间9.2%(n=12 668)发生复合终点事件。
  • 与精制谷物最低摄入组(<50 g/天)相比,最高摄入组(≥350 g/天或约7份/天)全因死亡HR 1.27(95%CI 1.11–1.46;趋势P=0.004)。
  • 与精制谷物最低摄入组相比,最高摄入组主要心血管事件HR 1.33(95%CI 1.16–1.52;趋势P<0.001)。
  • 与精制谷物最低摄入组相比,最高摄入组复合终点HR 1.28(95%CI 1.15–1.42;趋势P<0.001)。
  • 精制谷物摄入越高收缩压越高;全谷物或白米摄入与健康结局无显著关联。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究;原文未提及证据等级或推荐强度。
  • 局限:观察性设计不能证明因果;膳食评估依赖食物频率问卷;原文未提及其他局限。

对床旁实践的改变

  • 原文结论提示全球范围内应考虑减少精制谷物消费以降低死亡和主要心血管事件风险;未提及对急诊或ICU具体做法的影响。

指南或共识出处

  • 原文未提及指南或共识名称;研究为PURE(Prospective Urban and Rural Epidemiology)研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the association between intakes of refined grains, whole grains, and white rice with cardiovascular disease, total mortality, blood lipids, and blood pressure in the Prospective Urban and Rural Epidemiology (PURE) study.

DESIGN: Prospective cohort study.

SETTING: PURE study in 21 countries.

PARTICIPANTS: 148 858 participants with median follow-up of 9.5 years.

EXPOSURES: Country specific validated food frequency questionnaires were used to assess intakes of refined grains, whole grains, and white rice.

MAIN OUTCOME MEASURE: Composite of mortality or major cardiovascular events (defined as death from cardiovascular causes, non-fatal myocardial infarction, stroke, or heart failure). Hazard ratios were estimated for associations of grain intakes with mortality, major cardiovascular events, and their composite by using multivariable Cox frailty models with random intercepts to account for clustering by centre.

RESULTS: Analyses were based on 137 130 participants after exclusion of those with baseline cardiovascular disease. During follow-up, 9.2% (n=12 668) of these participants had a composite outcome event. The highest category of intake of refined grains (≥350 g/day or about 7 servings/day) was associated with higher risk of total mortality (hazard ratio 1.27, 95% confidence interval 1.11 to 1.46; P for trend=0.004), major cardiovascular disease events (1.33, 1.16 to 1.52; P for trend<0.001), and their composite (1.28, 1.15 to 1.42; P for trend<0.001) compared with the lowest category of intake (<50 g/day). Higher intakes of refined grains were associated with higher systolic blood pressure. No significant associations were found between intakes of whole grains or white rice and health outcomes.

CONCLUSION: High intake of refined grains was associated with higher risk of mortality and major cardiovascular disease events. Globally, lower consumption of refined grains should be considered.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Swaminathan S, Dehghan M, Raj JM, et al. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. BMJ. 2021. PMID: 33536317. doi:10.1136/bmj.m4948

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。